Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)." This initiative aims to support the validation of molecular, cellular, and imaging biomarkers for cancer detection, diagnosis, prognosis, and treatment response, with applicants having the option to submit either a biphasic UH2/UH3 application for five years or a monophasic UH3 application for three years. The importance of this funding lies in its potential to enhance cancer risk assessment and treatment management through the development of clinically validated assays, which require collaboration among various scientific disciplines. Interested applicants can reach out to the Cancer Diagnosis Program at NCICDPNOFO@mail.nih.gov or call 240-276-5748 for further information, with the estimated project start date set for December 1, 2027, and the application closing date anticipated for February 8, 2027.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;